What is Clearmind Medicine Earnings Yield (Joel Greenblatt) %?
Clearmind Medicine's Enterprise Value for the quarter that ended in Jan. 2024 was C$0.00 Mil.
Clearmind Medicine's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was C$-6.09 Mil. Clearmind Medicine's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jan. 2024 was 95.24%.
The historical rank and industry rank for Clearmind Medicine's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
XCNQ:CMND'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -21046.51 Med: 0 Max: 129000
Current: 102.04
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Clearmind Medicine was 129000.00%. The lowest was -21046.51%. And the median was 0.00%.
XCNQ:CMND's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -14.33
vs XCNQ:CMND: 102.04
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Clearmind Medicine's Forward Rate of Return (Yacktman) % for the quarter that ended in Jan. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Clearmind Medicine Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Clearmind Medicine's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Clearmind Medicine Earnings Yield (Joel Greenblatt) % Chart
Competitive Comparison of Clearmind Medicine's Earnings Yield (Joel Greenblatt) %
For the Biotechnology subindustry, Clearmind Medicine's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearmind Medicine's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Clearmind Medicine's Earnings Yield (Joel Greenblatt) % falls into.
Clearmind Medicine Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Clearmind Medicines Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Oct. 2023 is calculated as
Clearmind Medicine's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-6.09 Mil.
Clearmind Medicine (XCNQ:CMND) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Clearmind Medicine Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Clearmind Medicine's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Clearmind Medicine (XCNQ:CMND) Business Description
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XCNQ:CMND has been successfully added to your 